- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Rossari Biotech's Q1 FY26 consolidated revenue rose 11% to Rs 543.7 Cr, driven by strong HPPC (+16%) and AHN (+12%) segment growth. EBITDA increased 4.6% to Rs 67.9 Cr, though margins tightened to 12.5%. PAT saw a 3.7% decrease to Rs 33.6 Cr. Management is progressing with capacity expansion projects across verticals, expected to commission over coming quarters. These strategic investments aim to boost manufacturing capabilities for high-growth sectors, anticipating value unlocking and growth acceleration from FY27.